---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-119757"
form_type: "8-K"
ticker: "SRZN"
cik: "0001824893"
company_name: "Surrozen, Inc./DE"
filed_at: "2026-03-23T23:59:59+00:00"
generated_at: "2026-05-15T09:23:39.881271+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Surrozen reports FY2025 net loss $242M; cash $89.2M; expects IND for SZN-8141 in H2 2026

## Summary
- Cash and equivalents $89.2M at Dec 31, 2025, up from $34.6M year-end 2024; additional $30.2M raised in early 2026 via ATM and warrant exercises.
- Full year net loss $242.0M ($32.37 per share) vs $63.6M in 2024, driven by non-cash PIPE-related charges (tranche liability, warrant revaluation).
- No collaboration revenue in 2025 vs $10M in 2024; research service revenue from terminated TCGFB deal was $3.5M.
- Received $5M milestone from Boehringer Ingelheim for SZN-413 after successful IND-enabling GLP tox study.
- On track to submit IND for SZN-8141 (retinal disease) to FDA in H2 2026; will present at ARVO in May 2026.

## SEC filing metadata
- accession: 0001193125-26-119757
- form_type: 8-K
- ticker: SRZN
- cik: 0001824893
- company_name: Surrozen, Inc./DE
- filed_at: 2026-03-23T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1824893/000119312526119757/0001193125-26-119757-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1824893/000119312526119757/srzn-20260323.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-119757
- JSON: https://secwatch.observer/filing/0001193125-26-119757.json
- Plain text: https://secwatch.observer/filing/0001193125-26-119757.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.